| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Bernard Blotner last filed a Form 4 in August 2024, as Director at PURE. Bernard Blotner's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 10,000 shares of PURE. Net of sales, the PURE filings show accumulation of 10,000 shares.
Bernard Blotner has 3 Form 4 filings on record from March 2023 to August 2024, all as Director at Pure Bioscience (PURE), 2023–2024.
The 3 reported transactions were 2 option or other derivative awards and 1 open-market purchase.
Counted by filing, the open-market trades come to 1 purchase worth about $1K and no sales.
The only open-market purchase was 10,000 shares of PURE at an average $0.13 on March 21, 2023, about $1K.
Shares as reported in the last Form 4 for each company; the most recent is from August 2024. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Mar 21, 2023 | PURE Pure Bioscience, Inc. | Director | Buy | 10,000 | $0.13 | $1,299.00 | New |